Next Article in Journal
Cerebrospinal Fluid Biomarkers in Childhood Leukemias
Previous Article in Journal
MINDIN Exerts Protumorigenic Actions on Primary Prostate Tumors via Downregulation of the Scaffold Protein NHERF-1
Previous Article in Special Issue
Satellitosis, a Crosstalk between Neurons, Vascular Structures and Neoplastic Cells in Brain Tumours; Early Manifestation of Invasive Behaviour
Open AccessReview

The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma

1
Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
2
Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Donat Kögel, Christel Herold-Mende and Benedikt Linder
Cancers 2021, 13(3), 437; https://doi.org/10.3390/cancers13030437
Received: 31 December 2020 / Revised: 19 January 2021 / Accepted: 21 January 2021 / Published: 24 January 2021
(This article belongs to the Special Issue Targeted Therapies for the Treatment of Glioblastoma)
Glioblastoma is one of the most treatment-refractory human malignancies, and despite techniques that have allowed scientists and clinicians to better understand the molecular underpinnings of resistance, little progress has been made in improving the survival of patients with glioblastoma. We posit that dysregulated Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling represents one major hub of tumorigenesis and resistance to medical therapies and that clinical study of its targeted inhibition is warranted, as well as highlighting the lessons learned from historical investigation going forward.
Glioblastoma remains one of the deadliest and treatment-refractory human malignancies in large part due to its diffusely infiltrative nature, molecular heterogeneity, and capacity for immune escape. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway contributes substantively to a wide variety of protumorigenic functions, including proliferation, anti-apoptosis, angiogenesis, stem cell maintenance, and immune suppression. We review the current state of knowledge regarding the biological role of JAK/STAT signaling in glioblastoma, therapeutic strategies, and future directions for the field. View Full-Text
Keywords: JAK; STAT3; glioblastoma; immunotherapy; resistance JAK; STAT3; glioblastoma; immunotherapy; resistance
Show Figures

Figure 1

MDPI and ACS Style

Ou, A.; Ott, M.; Fang, D.; Heimberger, A.B. The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma. Cancers 2021, 13, 437. https://doi.org/10.3390/cancers13030437

AMA Style

Ou A, Ott M, Fang D, Heimberger AB. The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma. Cancers. 2021; 13(3):437. https://doi.org/10.3390/cancers13030437

Chicago/Turabian Style

Ou, Alexander; Ott, Martina; Fang, Dexing; Heimberger, Amy B. 2021. "The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma" Cancers 13, no. 3: 437. https://doi.org/10.3390/cancers13030437

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop